Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 11/20 | 0.67 |
| ▸ | CACNB1 | Q02641 | 11/20 | 0.67 |
| ▸ | CACNA1B | Q00975 | 10/20 | 0.67 |
| ▸ | CACNA1C | Q13936 | 5/20 | 0.59 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.59 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.58 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GPX4 | P36969 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4271703 | 0.91 | CACNA2D1 (0.66) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL4273386 | 0.89 | CACNA2D1 (0.67) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL4274014 | 0.87 | CACNA2D1 (0.65) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL4279868 | 0.85 | CACNA2D1 (0.59) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL4271451 | 0.85 | KMT2A (0.60) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL4284632 | 0.81 | CACNA2D1 (0.67) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL4279084 | 0.81 | CACNA2D1 (0.58) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL4278891 | 0.81 | CACNA2D1 (0.70) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL5266814 | 0.80 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL8239746 | 0.78 | CACNA2D1 (0.56) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | claimed |
| EP-1976841-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2008-10-08 | — | — | EP | claimed |
| WO-2007071035-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-06-28 | — | — | WO | claimed |
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | RYR2, CACNA1E, RYR1 | CACNA2D1 45/4885CACNB1 18/4885CACNA1B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.